87 research outputs found

    Paraoxonase 1 activity and genotyping in systemic lupus erythematosus and their relationships with cardiovascular complications

    Get PDF
    Introduction: Systemic lupus erythematosus (SLE) is characterized by an enhanced risk of atherosclerosis and cardiovascular diseases (CVD). Human serum paraoxonase 1 (PON1), an antioxidant enzyme closely associated with high density lipoprotein (HDL), has been implicated in the prevention of low density lipoprotein (LDL) oxidation, and these may provide HDL-associated protection against atherosclerosis. The Aim: Our objective was to evaluate PON1 activity and genotypes in SLE patients and their relationships to cardiovascular complications and some other risk factors of cardiovascular diseases in those patients. Patient and Methods: Thirty SLE patients, subdivided into patients with CVD and without CVD, and fifteen matched healthy control subjects were studied. Laboratory investigations included lipid profile, lupus anticoagulants (LA), anticardiolipin antibodies (aCL). PON1 activity was determined by paraoxon substrate. PON1 genotyping was conducted by PCR amplification, followed by polymorphism-specific restriction enzyme digestion and gel electrophoresis. Results: Our study revealed that PON1 activity was significantly decreased in SLE patients groups compared to controls and in SLE patients with CVD compared to those without CVD (

    Validated stability-indicating spectrofluorimetric methods for the determination of ebastine in pharmaceutical preparations

    Get PDF
    Two sensitive, selective, economic, and validated spectrofluorimetric methods were developed for the determination of ebastine (EBS) in pharmaceutical preparations depending on reaction with its tertiary amino group. Method I involves condensation of the drug with mixed anhydrides (citric and acetic anhydrides) producing a product with intense fluorescence, which was measured at 496 nm after excitation at 388 nm

    Perioperative oxygen fraction – effect on surgical site infection and pulmonary complications after abdominal surgery: a randomized clinical trial. Rationale and design of the PROXI-Trial

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>A high perioperative inspiratory oxygen fraction may reduce the risk of surgical site infections, as bacterial eradication by neutrophils depends on wound oxygen tension. Two trials have shown that a high perioperative inspiratory oxygen fraction (Fi<smcaps>O</smcaps><sub>2 </sub>= 0.80) significantly reduced risk of surgical site infections after elective colorectal surgery, but a third trial was stopped early because the frequency of surgical site infections was more than doubled in the group receiving Fi<smcaps>O</smcaps><sub>2 </sub>= 0.80. It has not been settled if a high inspiratory oxygen fraction increases the risk of pulmonary complications, such as atelectasis, pneumonia and respiratory failure. The aim of our trial is to assess the potential benefits and harms of a high perioperative oxygen fraction in patients undergoing abdominal surgery.</p> <p>Methods and design</p> <p>The PROXI-Trial is a randomized, patient- and assessor blinded trial of perioperative supplemental oxygen in 1400 patients undergoing acute or elective laparotomy in 14 Danish hospitals. Patients are randomized to receive either 80% oxygen (Fi<smcaps>O</smcaps><sub>2 </sub>= 0.80) or 30% oxygen (Fi<smcaps>O</smcaps><sub>2 </sub>= 0.30) during surgery and for the first 2 postoperative hours. The primary outcome is surgical site infection within 14 days. The secondary outcomes are: atelectasis, pneumonia, respiratory failure, re-operation, mortality, duration of postoperative hospitalization, and admission to intensive care unit. The sample size allows detection of a 33% relative risk reduction in the primary outcome with 80% power.</p> <p>Discussion</p> <p>This trial assesses benefits and harms of a high inspiratory oxygen fraction, and the trial may be generalizable to a general surgical population undergoing laparotomy.</p> <p>Trial registration</p> <p>ClinicalTrials.gov identifier: NCT00364741.</p

    A systematic review of physical activity and sedentary behaviour research in the oil-producing countries of the Arabian Peninsula

    Full text link
    • …
    corecore